Elanco Animal Health (NYSE:ELAN) Director Lawrence Erik Kurzius Purchases 40,000 Shares

Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius acquired 40,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the purchase, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Elanco Animal Health Stock Up 2.1%

Elanco Animal Health stock traded up $0.49 during mid-day trading on Friday, hitting $24.05. The company had a trading volume of 4,748,443 shares, compared to its average volume of 5,728,003. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The company has a market capitalization of $12.02 billion, a PE ratio of -58.66, a price-to-earnings-growth ratio of 1.47 and a beta of 1.67. The stock’s 50 day moving average price is $24.56 and its two-hundred day moving average price is $24.01. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Institutional Trading of Elanco Animal Health

Several hedge funds have recently bought and sold shares of the stock. Nykredit A S bought a new position in shares of Elanco Animal Health in the second quarter worth about $356,000. B. Metzler seel. Sohn & Co. AG grew its stake in shares of Elanco Animal Health by 55.7% during the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 100,736 shares of the company’s stock valued at $2,479,000 after acquiring an additional 36,038 shares during the period. Proficio Capital Partners LLC bought a new position in shares of Elanco Animal Health during the 2nd quarter valued at approximately $260,000. Alyeska Investment Group L.P. purchased a new stake in Elanco Animal Health in the 2nd quarter worth approximately $36,875,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Elanco Animal Health by 14.7% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 10,953 shares of the company’s stock worth $270,000 after acquiring an additional 1,405 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on ELAN. Morgan Stanley lifted their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. UBS Group increased their target price on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Finally, KeyCorp upped their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.